You are viewing an incomplete version of our website. Please click to reload the website as full version.

TNFSF10 antibody (Tumor Necrosis Factor (Ligand) Superfamily, Member 10)

Details for Product anti-TNFSF10 Antibody No. ABIN967538, Supplier: Log in to see
Antigen
  • TRAIL
  • tl2
  • apo2l
  • cd253
  • trail
  • apo-2l
  • trail1
  • xtrail1
  • APO2L
  • Apo-2L
  • CD253
  • TL2
  • A330042I21Rik
  • AI448571
  • APO-2L
  • Ly81
  • Trail
Alternatives
anti-Human TNFSF10 antibody for Functional Studies
Reactivity
Human
263
65
26
2
2
1
Host
Mouse
185
99
24
2
1
Clonality (Clone)
Monoclonal ()
Conjugate
This TNFSF10 antibody is un-conjugated
33
17
13
9
6
3
2
1
1
1
1
1
1
1
1
1
Application
Western Blotting (WB)
198
119
83
47
24
23
16
14
13
11
10
8
5
2
2
2
2
2
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Brand BD Pharmingen™
Immunogen Recombinant Human TRAIL protein
Clone B35-1
Isotype IgG2b, kappa
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Alternative Name TRAIL (TNFSF10 Antibody Abstract)
Background TRAIL (TNF-Related Apoptosis-Inducing Ligand) also known as Apo2L is a member of the TNF ligand family. TRAIL is a type II membrane protein which may be expressed as full-length, cell surface associated protein as well as in a soluble form. Both surface and soluble forms of TRAIL rapidly induce apoptosis on a wide range of cell lines. TRAIL-mediated apoptosis has been shown to involve the activation of ICE-related proteases/caspases, and is blocked by over-expression of the Ced-3 protease inhibitor, CrmA. TRAIL has also been reported to induce the transcription factor, NF-kappaB, in a cell typespecific manner. Three TRAIL receptors, DR4, DR5 and DcR1/TRID have been identified. Surface human TRAIL migrates at ~32 kDa by SDS/PAGE, soluble, human recombinant TRAIL migrates at 28 kDa by SDS/PAGE and has also been observed in solution as a multimeric, 80 kDa form. The B35-1 antibody recognizes human TRAIL. A recombinant human TRAIL protein fragment corresponding to amino acids 32-115 was used as immunogen. TRAIL has been renamed as CD253 recently.
Synonyms: TRAIL, APO-2L, TL2
Molecular Weight 32 kDa (surface), 28 kDa (soluble)
Research Area Cancer, Apoptosis/Necrosis
Pathways Apoptosis
Application Notes WI-38 human diploid fibroblasts (ATCC CC L75) are suggested as a positive control for Western blot analysis.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store undiluted at 4°C.
Supplier Images
Western Blotting (WB) image for anti-TNFSF10 antibody (Tumor Necrosis Factor (Ligand) Superfamily, Member 10) (ABIN967538) Western blot analysis of TRAIL. WI-38 human diploid fibroblasts probed with anti-huma...
 image for anti-TNFSF10 antibody (Tumor Necrosis Factor (Ligand) Superfamily, Member 10) (ABIN967538) anti-Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10) antibody (Image 2)
Western Blotting (WB) image for anti-TNFSF10 antibody (Tumor Necrosis Factor (Ligand) Superfamily, Member 10) (ABIN967538) anti-Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10) antibody (Image 3)
Product cited in: Wang, Wang, Hernandez et al.: "Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells." in: The Journal of biological chemistry, Vol. 277, Issue 39, pp. 36602-10, 2002 (PubMed).

Sheridan, Marsters, Pitti et al.: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors." in: Science (New York, N.Y.), Vol. 277, Issue 5327, pp. 818-21, 1997 (PubMed).

Mariani, Matiba, Armandola et al.: "Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells." in: The Journal of cell biology, Vol. 137, Issue 1, pp. 221-9, 1997 (PubMed).

Marsters, Pitti, Donahue et al.: "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA." in: Current biology : CB, Vol. 6, Issue 6, pp. 750-2, 1997 (PubMed).

Wiley, Schooley, Smolak et al.: "Identification and characterization of a new member of the TNF family that induces apoptosis." in: Immunity, Vol. 3, Issue 6, pp. 673-82, 1996 (PubMed).

Pitti, Marsters, Ruppert et al.: "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family." in: The Journal of biological chemistry, Vol. 271, Issue 22, pp. 12687-90, 1996 (PubMed).